The stock of Cellectis SA (ADR) (NASDAQ:CLLS) gapped up by $0.23 today and has $24.23 target or 6.00% above today’s $22.86 share price. The 6 months technical chart setup indicates low risk for the $819.41M company. The gap was reported on Apr, 20 by Barchart.com. If the $24.23 price target is reached, the company will be worth $49.16M more. About 52,435 shares traded. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 10.62% since September 13, 2016 and is downtrending. It has underperformed by 20.55% the S&P500.
Pampa Energia SA (NYSE:PAM) had an increase of 15.35% in short interest. PAM’s SI was 951,200 shares in April as released by FINRA. Its up 15.35% from 824,600 shares previously. With 211,500 avg volume, 5 days are for Pampa Energia SA (NYSE:PAM)’s short sellers to cover PAM’s short positions. The SI to Pampa Energia SA’s float is 1.89%. About 71,485 shares traded. Pampa Energia S.A. (ADR) (NYSE:PAM) has risen 104.98% since September 13, 2016 and is uptrending. It has outperformed by 95.05% the S&P500.
Among 3 analysts covering Cellectis (NASDAQ:CLLS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cellectis had 3 analyst reports since April 5, 2016 according to SRatingsIntel. The rating was initiated by Wells Fargo on Tuesday, February 28 with “Outperform”. The company was initiated on Tuesday, April 5 by Ladenburg Thalmann.
Analysts await Cellectis SA (ADR) (NASDAQ:CLLS) to report earnings on May, 10. They expect $-0.56 earnings per share, up 39.13% or $0.36 from last year’s $-0.92 per share. After $-0.38 actual earnings per share reported by Cellectis SA (ADR) for the previous quarter, Wall Street now forecasts 47.37% negative EPS growth.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The company has market cap of $819.41 million. The Firm specializes in the research, development and commercialization of rational genome engineering technologies. It currently has negative earnings. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
